Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label rotigotine monotherapy in adolescents with restless legs syndrome
2021-003403-18Phase 3
- Sponsor
- UCB
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rotigotine in restless legs syndrome (RLS), sponsored by UCB. Primary endpoint: Occurrence of treatment-emergent adverse events.
02
Drugs
rotigotine
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on 2021-003403-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003403-18.